
Oncology NEWS International
- Oncology NEWS International Vol 17 No 2
- Volume 17
- Issue 2
M.D. Anderson and AstraZeneca form neuropathic pain alliance
M.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy.
HOUSTONM.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy. The alliance will focus on identifying neurobiological differences between cancer patients who develop such pain and those who do not, and better understanding the mechanisms through which chemotherapies cause peripheral nerve dysfunctions.
Articles in this issue
about 18 years ago
NLST article not balanced, critic of screening trial assertsabout 18 years ago
Good nilotinib responses in imatinib-resistant AP-CMLabout 18 years ago
Virus linked to Merkel cell carcinomaabout 18 years ago
Benefit of adjuvant RT/CT for pancreatic ca affirmedabout 18 years ago
Recurrence Score helps select node+ pts for chemoabout 18 years ago
For resectable liver mets: Preop chemotherapy or not?about 18 years ago
Plerixafor boosts stem cell mobilization in myeloma ptsabout 18 years ago
MRI shows second-hand smoke damageabout 18 years ago
Assay has high sensitivity for hard-to-detect SLN metsabout 18 years ago
Dasatinib effective in imatinib resistant/intolerant CMLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















